Our Mission

---

Our Mission

Bridging the Gap Between Breakthrough & Patient Impact.

Developing novel therapeutics is an arduous journey. Too often, innovative ideas stall before reaching the clinic not because the science failed, but because the strategy was missing, especially when navigating the FDA approval pathways.

CellGene Nexus was founded to change that narrative. We bring deep, hands-on oncology expertise, alongside robust knowledge in gene therapy and translational research, to help founders and researchers move from preclinical proof to clinical reality with certainty.

We don't just advise; we architect the path forward.

Our Edge

With over 15 years of oncology expertise, we specialize in translational research and regulatory science. Our preclinical strategy and experimental design, utilizing cells and humanized mouse models, are meticulously aligned with FDA approval pathways and IND standards. We focus on IND-enabling program development across toxicology, biodistribution, and efficacy studies—always with a GLP-aware approach. With more than 90 peer-reviewed publications and global presentations in precision medicine, we are deeply rooted in the Houston and Texas Medical Center innovation ecosystem.